Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexrazoxane for Epirubicin Cardiotoxicity in Breast Cancer Patients With Type 2 Diabetes
ChiCTR-IPR-16007759Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexrazoxane in breast cancer and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoints: Heart rate variability index, Echocardiographic index and 2 more. Started Oct 2012; status: recruiting.
02
Drugs
dexrazoxane
03
Conditions
breast cancertype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-16007759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16007759.